{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T11:05:03Z","timestamp":1776510303001,"version":"3.51.2"},"reference-count":21,"publisher":"British Editorial Society of Bone & Joint Surgery","issue":"11","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/online.boneandjoint.org.uk\/TDM"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Bone and Joint Surgery. British volume"],"published-print":{"date-parts":[[2012,11]]},"abstract":"<jats:p> Post-operative complications after total hip or knee replacement can delay recovery, prolong hospitalisation, increase rates of re-admission and, in the most severe cases, lead to long-term disability or even death. In this analysis of pooled data from four large, randomised, phase III clinical trials that compared the oral, direct Factor Xa inhibitor rivaroxaban with subcutaneous enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement (n = 12\u00a0729), the incidence of complications, including bleeding and adverse events related to surgery (such as wound infection, wound dehiscence and haemarthrosis) are reported. Interventions and procedures relating to surgery are also compared between the groups. Bleeding events, including excessive wound haematoma and surgical-site bleeding, occurred at similar rates in the rivaroxaban and enoxaparin groups. Over the total study duration, adverse surgical events occurred at a similar rate in the rivaroxaban group compared with the enoxaparin group after total knee replacement (2.26% vs 2.69%, respectively) and total hip replacement (1.48% vs 1.65%, respectively). Blood loss, wound drainage and transfusion requirements were also similar between the two groups. <\/jats:p><jats:p> This analysis shows that the incidence of adverse surgical events with rivaroxaban was similar to enoxaparin. <\/jats:p>","DOI":"10.1302\/0301-620x.94b11.28955","type":"journal-article","created":{"date-parts":[[2012,10,29]],"date-time":"2012-10-29T14:19:30Z","timestamp":1351520370000},"page":"1573-1578","source":"Crossref","is-referenced-by-count":37,"title":["The effects of rivaroxaban on the complications of surgery after total hip or knee replacement"],"prefix":"10.1302","volume":"94-B","author":[{"given":"M. R.","family":"Lassen","sequence":"first","affiliation":[{"name":"Spine Center Copenhagen, Clinical\rTrial Unit, Copenhagen University Hospital\rGlostrup, \rNdr. Ringvej 57, DK-2600, Glostrup, Denmark."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Gent","sequence":"additional","affiliation":[{"name":"McMaster University, Department\rof Medicine, 1200 Main Street West, Hamilton, Ontario L8N\r3Z5, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. K.","family":"Kakkar","sequence":"additional","affiliation":[{"name":"Thrombosis Research Institute, Emmanuel\rKaye Building, Manresa Road, Chelsea, London SW3\r6LR, UK."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. I.","family":"Eriksson","sequence":"additional","affiliation":[{"name":"Sahlgrenska Academy, University of Gothenburg, Orthopaedics\rDepartment, \u00a0Institute of Clinical Sciences, \u00a0SE-43180\rM\u00f6lndal, Sweden."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Homering","sequence":"additional","affiliation":[{"name":"Bayer Pharma AG, Aprather\rWeg 18a, 42113 Wuppertal, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. D.","family":"Berkowitz","sequence":"additional","affiliation":[{"name":"Global Clinical Development, Bayer HealthCare\rPharmaceuticals Inc., Montville, New\rJersey\r07045-1000, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. G. G.","family":"Turpie","sequence":"additional","affiliation":[{"name":"McMaster University, Department\rof Medicine, 237 Barton Street East, Hamilton, Ontario L8L\r2X2 , Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"42","reference":[{"key":"r1","doi-asserted-by":"publisher","DOI":"10.1086\/505451"},{"key":"r2","doi-asserted-by":"publisher","DOI":"10.2106\/JBJS.G.01370"},{"key":"r3","first-page":"565","volume":"70","author":"Frosch P","year":"2004","journal-title":"Acta Orthop Belg"},{"key":"r4","doi-asserted-by":"publisher","DOI":"10.2106\/JBJS.G.01371"},{"key":"r5","doi-asserted-by":"publisher","DOI":"10.2106\/JBJS.F.00163"},{"key":"r6","first-page":"27","volume":"89","author":"Parvizi J","year":"2007","journal-title":"J Bone Joint Surg [Am]"},{"key":"r7","doi-asserted-by":"publisher","DOI":"10.1002\/art.24060"},{"key":"r8","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2404"},{"key":"r9","unstructured":"No authors listed. National Institute for Clinical Excellence. Venous thromboembolism: reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital. http:\/\/www.nice.org.uk\/nicemedia\/live\/12695\/47195\/47195.pdf (date last accessed 11 September 2012)."},{"key":"r10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e3675"},{"key":"r11","doi-asserted-by":"publisher","DOI":"10.1302\/0301-620X.92B1.22751"},{"key":"r12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0800374"},{"key":"r13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60880-6"},{"key":"r14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa076016"},{"key":"r15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60734-0"},{"key":"r16","doi-asserted-by":"publisher","DOI":"10.1160\/TH10-09-0601"},{"key":"r17","unstructured":"No authors listed. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human use. http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E6_R1\/Step4\/E6_R1__Guideline.pdf (date last accessed 11 September 2012)."},{"key":"r18","doi-asserted-by":"publisher","DOI":"10.1302\/0301-620X.93B1.24987"},{"key":"r19","doi-asserted-by":"publisher","DOI":"10.1086\/502425"},{"key":"r20","first-page":"55","volume":"71","author":"Sanchez-Ballester J","year":"2005","journal-title":"Acta Orthop Belg"},{"key":"r21","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.162.13.1451"}],"container-title":["The Journal of Bone and Joint Surgery. British volume"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/online.boneandjoint.org.uk\/doi\/pdf\/10.1302\/0301-620X.94B11.28955","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/online.boneandjoint.org.uk\/doi\/full-xml\/10.1302\/0301-620X.94B11.28955","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/online.boneandjoint.org.uk\/doi\/pdf\/10.1302\/0301-620X.94B11.28955","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T18:42:19Z","timestamp":1629139339000},"score":1,"resource":{"primary":{"URL":"https:\/\/online.boneandjoint.org.uk\/doi\/10.1302\/0301-620X.94B11.28955"}},"subtitle":["Results from the RECORD programme"],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["10.1302\/0301-620X.94B11.28955"],"URL":"https:\/\/doi.org\/10.1302\/0301-620x.94b11.28955","relation":{},"ISSN":["0301-620X","2044-5377"],"issn-type":[{"value":"0301-620X","type":"print"},{"value":"2044-5377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}